David Fredrickson, AstraZeneca
January 29, 2021 09:53 AM ESTUpdated 12:51 PM
R&D

WCLC: As­traZeneca builds case for grow­ing ADC pipeline with dou­ble wins in ad­vanced lung can­cer

Kyle Blankenship

As part of its hard piv­ot to on­col­o­gy in re­cent years, As­traZeneca made a big bet on next-gen can­cer fight­ers with a multi­bil­lion-dol­lar deal in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

IN8bio’s Phase 1 AML da­ta; Lay­offs at Q32 Bio and Third Har­mon­ic

In­ven­ti­va cuts pipeline, lays off near­ly en­tire re­search team in bid to get to Phase 3 MASH read­out

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times